Taken together, these data indicate that hepatic TIMP3 can slow progression of NAFLD, and tumorigenesis, at least in part, through the regulation of ADAM17 activity. The gene discussed is ADAM17; the disease is metabolic dysfunction-associated steatotic liver disease.